
Roberto Caricchio, MD, discusses what trials of repurposed rheumatology drugs to treat COVID-19 cytokine storm have shown so far.... [Read More]
Roberto Caricchio, MD, discusses what trials of repurposed rheumatology drugs to treat COVID-19 cytokine storm have shown so far.... [Read More]
• By Randy Q. Cron, MD, PhD, & W. Winn Chatham, MD
The new coronavirus outbreak, COVID-19, reminds us how we have struggled to keep ahead of mutating pathogens through the ages.... [Read More]
• By Mark Gorelik, MD
A pediatric rheumatologist in the thick of treating children with COVID-19 confronts a new and evolving syndrome.... [Read More]
ACR CONVERGENCE 2020—The ACR’s first fully virtual annual meeting kicked off on Thursday, Nov. 5. During the Opening Session, ACR President Ellen M. Gravallese, MD, talked about how the specialty’s response during the pandemic has provided great hope and will help rheumatology become an even more essential specialty. At the first Plenary Session on Friday,… [Read More]
• By Josephine Mason & Kate Kelland
LONDON (Reuters)—Oxford University said on Wednesday it will study whether the prescription medicine, adalimumab (Humira), is an effective treatment for COVID-19 patients—the latest effort to repurpose existing drugs as potential coronavirus therapies. Adalimumab, which is sold by AbbVie, is a type of anti-inflammatory known as an anti-tumour necrosis factor (anti-TNF) drug. Recent studies have shown… [Read More]
• By Megan Brooks
NEW YORK (Reuters Health)—Immunomodulatory therapy is not recommended for most children with COVID-19 who typically will have a mild to moderate course of illness, experts advise in a guidance document in the Journal of the Pediatric Infectious Diseases Society.1 For children with severe or critical COVID-19, immunomodulatory agents “may be beneficial,” but the risks and… [Read More]
• By Marilynn Larkin
NEW YORK (Reuters Health)—COVID-19-infected patients with rheumatic disease were more likely to experience respiratory failure than those without rheumatic disease, according to a retrospective study in China. “Immune dysregulation underlying rheumatic diseases may affect the disease manifestation of COVID-19,” Dr. Jixin Zhong of Huazhong University of Science and Technology, Wuhan, tells Reuters Health by email…. [Read More]
• By Catherine Kolonko
At the Loma Linda University Medical Center, Calif., rheumatologists play a key consulting role for COVID-19 patients who may benefit from the use of biologic treatments…... [Read More]
• By Candice Reyes, MD, RhMSUS
The uncertainty is certain Let us draw up the curtain Unmask this serial killer’s intention. Attack of its clones gone viral Made distancing societal Disrupting every human convention. Humble hydroxychloroquine Now forced into the scene Telehealth bridges our care. Drive-thru testing PPE and sanitizing Social media fills the air. But let’s not be deceived This… [Read More]
• By Megan Brooks
NEW YORK (Reuters Health)—Treatment with the interleukin-1 blocker anakinra appears to improve respiratory symptoms and reduced signs of cytokine storm in nearly three-quarters of patients with acute respiratory distress and cytokine release syndrome from COVID-19 in a small retrospective study from Italy. “Our study is the first to suggest that a high dose of the… [Read More]
Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.
Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.
Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.